Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review
B Meiser, WKT Wong, M Peate, C Julian-Reynier, J Kirk, G Mitchell
HEREDITARY CANCER IN CLINICAL PRACTICE | BMC | Published : 2017
BACKGROUND: Selective estrogen receptor modulators, such as tamoxifen, reduce breast cancer risk by up to 50% in women at increased risk for breast cancer. Despite tamoxifen's well-established efficacy, many studies show that most women are not taking up tamoxifen. This systematic literature review aimed to identify the motivators and barriers to tamoxifen use 's amongst high-risk women. METHODS: Using MEDLINE, PsycINFO, and Embase plus reviewing reference lists of relevant articles published between 1995 and 2016, 31 studies (published in 35 articles) were identified, which addressed high-risk women's decisions about risk-reducing medication to prevent breast cancer and were peer-reviewed p..View full abstract
Awarded by Cancer Council of New South Wales
Awarded by National Health and Medical Research Council Australia
Awarded by National Breast Cancer Foundation
D This work was funded by a Strategic Partnership Grant from Cancer Council of New South Wales (ID SRP 13-02). Bettina Meiser is supported Senior Research Fellowship Level B (ID 1078523) from the National Health and Medical Research Council Australia. Michelle Peate is currently supported by a National Breast Cancer Foundation Early Career Fellowship (ECG-15-005).